Status:
COMPLETED
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
Lead Sponsor:
NantCell, Inc.
Collaborating Sponsors:
Takeda
Conditions:
Adenocarcinoma of the Pancreas
Advanced Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
AMG 479 is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF-1R). Signaling through IGF-1R plays an important role in the regulation of ce...
Eligibility Criteria
Inclusion
- Untreated metastatic adenocarcinoma of the pancreas
- Adequate hematologic, renal and liver function
- Eastern Cooperative Oncology Group (ECOG) 0 or 1
Exclusion
- Prior chemotherapy or radiotherapy for pancreatic cancer
- Central nervous system metastases
- External biliary drain
Key Trial Info
Start Date :
April 7 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 12 2012
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT01231347
Start Date
April 7 2011
End Date
December 12 2012
Last Update
July 16 2024
Active Locations (152)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Fullerton, California, United States, 92835
2
Research Site
La Jolla, California, United States, 92093-0957
3
Research Site
Los Angeles, California, United States, 90095-1772
4
Research Site
Los Angeles, California, United States, 90095